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Abstract
Extracellular fibrinolysis, controlled by the membrane-bound
fibrinolytic system, is involved in cartilage damage and
rheumatoid arthritis (RA) synovitis. Estrogen status and
metabolism seem to be impaired in RA, and synoviocytes show
receptors for estrogens. Our aims in this study were to evaluate
in healthy and RA synoviocytes the effects of Raloxifene (RAL),
a selective estrogen receptor modulator (SERM), on:
proliferation; the components of the fibrinolytic system; and
chemoinvasion. The effects of RAL were studied in vitro on
synoviocytes from four RA patients and four controls.
Proliferation was evaluated as cell number increase, and
synoviocytes were treated with 0.5 µM and 1 µM RAL with and
without urokinase-plasminogen activator (u-PA) and anti-u-PA/
anti-u-PA receptor (u-PAR) antibodies. Fibrinolytic system
components (u-PA, u-PAR and plasminogen activator inhibitor
(PAI)-1) were assayed by ELISA with cells treated with 0.5 µM
and 1 µM RAL for 48 h. u-PA activity was evaluated by
zymography and a direct fibrinolytic assay. U-PAR/cell and its
saturation were studied by radioiodination of u-PA and a u-PA
binding assay. Chemoinvasion was measured using the Boyden
chamber invasion assay. u-PA induced proliferation of RA
synoviocytes was blocked by RAL (p < 0.05) and antagonized
by antibodies alone. The inhibitory effect of RAL was not additive
with u-PA/u-PAR antagonism. RA synoviocytes treated with
RAL showed, compared to basal, higher levels of PAI-1 (10.75
± 0.26 versus 5.5 ± 0.1 µg/106 cells, respectively; p < 0.01),
lower levels of u-PA (1.04 ± 0.05 versus 3.1 ± 0.4 ng/106 cells,
respectively; p < 0.001), and lower levels of u-PAR (11.28 ±
0.22 versus 23.6 ± 0.1 ng/106 cells, respectively; p < 0.001).
RAL also significantly inhibited u-PA-induced migration. Similar
effects were also shown, at least partially, in controls. RAL exerts
anti-proliferative and anti-invasive effects on synoviocytes,
mainly modulating u-PAR and, to a lesser extent, u-PA and PAI-
1 levels, and inhibiting cell migration and proliferation.
Introduction
It is well known that sex hormones are implicated in the
immune response. Estrogens enhance humoral immunity,
while androgens and progesterone are natural immune-sup-
pressors [1]. In rheumatoid arthritis (RA), sex hormones fuel
synovitis. Synovial macrophages, monocytes and lymphocytes
[2] possess functional androgen and estrogen receptors and
metabolize gonadal hormones [3]. In RA, an association of
estrogen gene polymorphism with age at onset has been
observed [4].
DMEM = Dulbecco's modified Eagle medium; ECM = extracellular matrix; ELISA = enzyme-linked immunosorbent assay; FCS = fetal calf serum; mAb 
= monoclonal antibody; MMP = matrix metalloproteinase; PAI = plasminogen activator inhibitor; RA = rheumatoid arthritis; RAL = Raloxifene; SERM 
= selective receptor estrogen modulator; TIMP = tissue inhibitor of matrix metalloproteinase; u-PA = urokinase-type plasminogen activator; u-PAR = 
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In both male and female RA patients, low levels of androgens
and a low androgen/estrogen ratio have been reported [5].
This supports a possible pathogenic immunosuppressive role
for decreased androgen levels. In RA, normal serum androgen
and low estrogen levels, but high synovial fluid estrogen and
lower androgen levels, indicate that peripheral sex hormone
metabolism may be involved in the manifestations of the dis-
ease and seems to play an important role in the immune-inflam-
matory local response [6].
A recent study provides a link between estrogen receptors
(ER-alpha) on fibroblast-like synoviocytes and regulation of
extracellular matrix (ECM) functionality by the system of matrix
metalloproteinases (MMPs)/tissue inhibitors of matrix metallo-
proteinases (TIMPs) [7]. The expression and activity of MMPs,
as well as the levels of TIMPs, is stimulated by 17beta-estra-
diol, but inhibited by progesterone.
Excessive extracellular proteolysis characterizes neoplastic
cell invasion [8], tumor- or inflammation-associated angiogen-
esis [9] and breakdown of the articular cartilage in osteoarthri-
tis [10]. As well as MMPs, the cell-associated serine
proteases of the plasminogen activator/plasminutes system
are also involved in extracellular proteolysis required for cell
invasion, possibly including cartilage and subcondral bone
degradation in RA.
In the fibrinolytic system, the urokinase-type plasminogen acti-
vator (u-PA) interacts with its membrane receptor (u-PAR) and
activates the single-chain proenzyme plasminogen to the two-
chain broad-spectrum serine proteinase plasmin, which is able
to degrade ECM both directly and indirectly through activation
of secreted pro-MMPs.
Membrane-type MMP undergoes a plasmin-dependent activa-
tion that enables it to activate membrane receptor-bound pro-
gelatinase A, thus triggering a multienzyme cascade leading to
ECM destruction and subsequent cell invasion [11]. Addition-
ally, cell-associated proteases are required for the activity of
pro-angiogenic factors, which sustain the synovial pannus
growth [12].
Synovial cells express membrane u-PAR, and cultured RA syn-
oviocytes display a higher production of plasminogen activator
inhibitor (PAI)-1 than in osteoarthritis and normal synoviocytes
[13], suggesting that the plasminogen activator/plasminutes
system is involved in the inflammatory remodeling of connec-
tive tissues occurring in arthritic joints. Beside its function in
the plasminogen activation process, the u-PA/u-PAR interac-
tion also induces plasmin-independent events, such as chem-
otaxis and chemokinesis [14], the proliferation [15,16] and
differentiation [17] of RA synoviocytes and the autocrine
secretion of u-PA [17]. Recently, our group has shown that, in
healthy synoviocytes, the u-PA/u-PAR interaction determines
chemotaxis, chemoinvasion and proliferation in a dose-
dependent fashion [18].
More recently, we have shown that RA synoviocytes over-
express u-PAR and PAI-1, under-express u-PA, and are more
prone than their normal counterpart to spontaneous and u-PA-
challenged invasion and proliferation [19].
Raloxifene (RAL) is a selective estrogen receptor modulator
(SERM) [20,21] with anti-estrogen activity in uterus and
breast tissues and pro-estrogen activity in bone [22,23]. In
post-menopausal women, RAL is widely used in the prevention
and treatment of osteoporosis due to its anti-resorptive activity
and established efficacy in reducing the risk of vertebral frac-
ture [24].
Depending on the endocrine balance, synoviocyte activity can
be reduced or enhanced, leading to amelioration or exacerba-
tion of synovitis, respectively. These considerations provide a
link between hormonal status and the mechanism of ECM
destruction in RA and open new avenues for possible future
therapeutic intervention. While the regulatory effect of estro-
gen is partly targeted to synoviocyte-associated MMPs and
TIMPs [7], little is known about the effects of RAL on healthy
and RA synoviocytes and their fibrinolytic pattern.
Therefore, our aim was to observe the effects of RAL on the
fibrinolytic components (u-PA, u-PAR and PAI-1) of RA synovi-
ocytes in order to modulate their levels and to reduce their
fibrinolytic-dependent cellular proliferation and invasion.
Materials and methods
Patients
Sex and age matched patients with RA and healthy controls
were used as a source of synoviocytes. Synovial tissue was
obtained from four RA patients undergoing surgery for syn-
oviectomy or joint replacement, and from four controls under-
going orthopaedic surgery for knee trauma. Informed consent
was obtained from the patients enrolled in this study and eth-
ics approval was given by the local ethics committee.
Synovial cell cultures
Synovia was removed from knee joints, cut and subjected to a
mild proteolytic treatment (0.05% trypsin, 0.5 mM EDTA in
phosphate buffer saline, for 10 minutes at 37°C under gentle
shaking). Trypsin was neutralized with FCS (Celbio, Milano,
Italy) and cells were plated in culture dishes with RPMI 1640
(Cambrex Bio Science, Milano, Italy) supplemented with 10%
FCS, 2 mM glutamine (Cambrex Bio Science) and penicillin-
streptomycin (Cambrex Bio Science). Cell monolayers were
used within the seventh passage in culture. The cells were
considered type B fibroblast-like synoviocytes if negative by
staining with anti-CD69, anti-CD14, anti-CD11b and anti-
CD11c (Santa Cruz Biotechnology, Santa Cruz, CA, USA),
positive by staining for the enzyme uridine-diphospho glucoseAvailable online http://arthritis-research.com/content/7/6/R1244
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dehydrogenase, and if they had a spindle-shaped, fibroblast-
like morphologic appearance.
RAL (Lilly, Sesto Fiorentino (FI), Italy) was dissolved in metha-
nol 100 mmol and further diluted with culture medium. Sam-
ples were analyzed both in basal conditions and after
treatment with RAL (48 h). In preliminary experiments, we
tested the effects of different doses of RAL in order to identify
which dose would be more effective on synoviocytes without
a lethal effect. Thus, the concentrations of 0.5 µM and 1 µM
RAL were chosen for further experiments and used in this
study. These concentrations were approved by the manufac-
turer (Lilly) and seem to be comparable with normal therapeu-
tic doses, even if it is impossible to know which dose really
reaches the synovia.
A431 cell culture
A431 is a human epidermoid cancer cell line from a cervix
squamous cell carcinoma. A431 cells were cultivated in
DMEM with 4.5 g/L glucose (Cambrex Bio Science), supple-
mented with 10% FCS, 2 mM glutamine and penicillin-strep-
tomycin. When cells were at confluence they were washed
and incubated with DMEM 0.2% FCS for 48 h. Then the con-
ditioned medium was centrifuged to remove particles and
stocked at -80°C. It was used as a chemoattractant reagent in
the chemoinvasion assay because of its known property to
secrete chemoattractant soluble factors [25-27].
Proliferation assay
Cell growth was quantified in subconfluent cell monolayers.
Synoviocytes were seeded in 24 multi-well plates (15,000
cells/well) with 10% FCS in RPMI 1640. After 48 h incuba-
tion, cells were washed three times with serum-free medium
and incubated in 0.2% FCS medium for an additional 48 h.
Cells were then incubated for 48 h in 10% FCS medium (pos-
itive control); 0.2% FCS medium (negative control); 0.2%
FCS with u-PA (Serono, Roma, Italy) 500 ng/ml with/without
u-PA or u-PAR antagonists. The agonists were anti-human u-
PA monoclonal antibody 5B4 (mAb 5B4) and anti-u-PAR mon-
oclonal antibody 3936 (mAb 3936) (American Diagnostica,
Montreal, Canada), which were used at 1.5 µg/ml. Both mAb
5B4 and mAb 3936 sterically impede the u-PA/u-PAR interac-
tion and were developed against the u-PA-binding site of u-
PAR. In preliminary experiments, we tested the effects of dif-
ferent doses of u-PA to identify what dose would be more effi-
cacious in inducing synoviocyte proliferation. Thus, the
concentration of 500 ng/ml u-PA was chosen.
Each experimental point was performed in triplicate. At the end
of incubation cells were counted. Samples were analyzed both
in basal conditions and after treatment with RAL 0.5 µM and 1
µM (48 h).
Analysis of u-PA, u-PAR and PAI-1 levels
Samples were analyzed for u-PAR, u-PA and PAI-1 using com-
mercially available ELISA kits (IMUBIND, American Diagnos-
tica, Montreal, Canada) according to the manufacturer's
instructions. Briefly, synoviocytes were seeded in six multi-well
plates (25,000 cells/well) with 10% FCS in RPMI 1640. After
48 h of incubation, cells were washed three times with serum-
free medium and incubated in 0.2% FCS medium for an addi-
tional 48 h. Cells were then treated with 0.5 µM or 1 µM RAL
for 48 h. At the end of incubation, cells were detached,
counted and lysed by a lysis buffer, as suggested by the man-
ufacturer. The lysates were replaced in their original well and
incubated for 1 h at 4°C to allow exhaustive extraction of unde-
tached material. Cell extracts were centrifuged and stocked at
-80°C until u-PAR analysis. Culture mediums were collected,
centrifuged and stocked at -80°C until u-PA and PAI-1 deter-
mination. The results were correlated to the standard curve,
within the range of linearity. Each sample was evaluated in trip-
licate and with two different dilutions. The u-PA assay reveals
u-PA antigen, independent of its catalytic activity; the u-PAR
and PAI-1 assays measure both occupied and unoccupied
receptor, and both free and u-PA-coupled PAI-1, respectively.
The sensibility levels were: 10 pg of u-PA/ml of sample; 0.1 ng
of u-PAR/ml of sample; 1 ng of PAI-1 /ml of sample.
Analysis of u-PA enzymatic activity
u-PA enzymatic activity was evaluated by zymography. Culture
medium samples were collected as described above and con-
centrated by centrifugation at 8,000 rpm for 30 minutes in
centricon tubes (Amicon Division, Beverly, MA, USA) with 30
kDa molecular weight cut-off pores. The samples were sub-
jected to SDS-PAGE (10%) under non-reducing conditions
and migrated proteins were transferred onto 0.45 µm pore-
size nitrocellulose filters (Bio-Rad Laboratories, Richmond,
California, USA) in a 0.04 M phosphate buffer (pH 6.5) and
run for 2 h under a current of 0.4 A. The nitrocellulose filter was
removed and placed on an indicating layer containing casein
and plasminogen. After overnight incubation at 37°C, u-PA
digestion of plasminogen showed clear bands of lysis in the
cloudy casein background, corresponding to the position of
plasminogen activators in the polyacrylamide gel. u-PA 0.1 U/
ml was used as a positive control. Zymograms were then
scanned. Samples were analyzed both in basal conditions and
after treatment with 0.5 µM or 1 µM RAL (48 h).
Because zymography was performed after protein separation
by SDS-PAGE, which uncoupled u-PA from PAI-1, we used a
direct fibrinolytic assay of cell membrane-associated plas-
minogen activators to study the final fibrinolytic balance of syn-
oviocytes. Briefly, synoviocyte monolayers were treated with
acidic wash (50 mM glycine-HCl buffer, pH 3.0, 0.1 M NaCl)
to uncouple both u-PA and u-PA/PAI-1 complexes from cell
surface u-PAR; Hepes buffer 0.5 M NaCl, pH 7.5, was added
after 3 minutes. Aliquots of the acidic wash were dotted onArthritis Research & Therapy    Vol 7 No 6    Guiducci et al.
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fibrin plates prepared according to a method previously
described [17] and fibrinolytic activity was evaluated after 16
h of incubation at 37°C, measuring the diameter of the lysis
areas. Each sample was evaluated in triplicate.
Radioiodination of u-PA and u-PA binding assay
u-PA was subjected to radioiodination with 125I-Na, using
Iodogen (Pierce Eurochemie BV, Holland), following the
instructions of the manufacturer. Iodinated protein was sepa-
rated from non-incorporated radioactivity by gel filtration on
Sephadex G-25 (Pharmacia, Milan, Italy). The specific activity
obtained in the preparation used in this study was 17.8 µCi/
µg. Saturation binding experiments were performed as previ-
ously described [28]. Binding experiments were performed
either on untreated cell monolayers or following acidic wash
(50 mM glycine-HCl buffer, pH 3.0, 0.1 M NaCl) to uncouple
u-PA from cell surface u-PAR; Hepes buffer 0.5 M NaCl, pH
7.5, was added after 3 minutes.
Migration assays
The Boyden chamber procedure was used to evaluate cell
migration [14]. The method is based on the passage of cells
across porous filters against a concentration gradient of the
migration effector. A 48-well micro-chemotaxis chamber (Neu-
roprobe, Gaithersburg, MD, USA) was used. The two wells
were separated by a polyvinyl-pyrrolidine-free polycarbonate
filter with an 8 µm pore size (Neuroprobe). To evaluate chem-
oinvasion, the filter was coated with Matrigel (50 µg/filter)
(Becton Dickinson Labware, Two Oak Park, Bedford, MA,
USA). Test solutions were dissolved in serum-free medium
and placed in the lower wells. 50 µl of cell suspension (12,500
cells) were added to each upper well. u-PA 100 ng/ml and/or
RAL (0.5 µM or 1 µM) were added to the upper and/or lower
well. In the experiment with neutralizing antibodies, the anti-u-
PA mAb 5B4 (1.5 µg/ml) was placed in the lower wells, while
the anti-u-PAR mAb 3936 (1.5 µg/ml) was incubated with the
cell suspension. The chamber was incubated at 37°C for 5 h
after which the filter was removed and fixed with methanol.
Non-migrating cells on the upper surface of the filter were
removed with a cotton swab. Cells were stained with Diff-
Quick (Mertz-Dade AG, Dade International, Milan, Italy) and
counted using a light microscope (40×) in 10 random fields
for each well. Mobilization was measured by the number of
cells moving across the Matrigel and the filter pores and
spread on the lower surface of the filter. Each experimental
point was performed in triplicate. Mean values of migrated
cells for each experimental point were calculated.
Statistics
A non-parametric Mann-Whitney test for independent samples
was used to compare results from healthy and RA synovio-
cytes for the levels of u-PA, u-PAR and PAI-1. The results were
expressed as mean ± standard deviation. The proliferation
induced by u-PA and RAL was evaluated by two tailed t-test
for independent samples and by analysis of variance (ANOVA
with Bonferroni correction). Migration was measured as a per-
centage of the healthy basal response and was expressed as
the mean ± standard error of the mean.
Results
u-PA-dependent proliferation of synoviocytes
u-PA induced a dose-dependent proliferation in both normal
and RA synoviocytes, reaching a maximum at 500 ng/ml (p <
0.001 for any dose in both cell lines) (Fig. 1). Proportionally, u-
PA increased cell proliferation in RA and healthy synoviocytes,
without reaching a significant difference between the two cell
lines at any u-PA dose.
These results show that u-PA has a pro-proliferative effect on
both healthy and RA synoviocytes and identify 500 ng/ml u-PA
as the minimal dose providing the maximal proliferative effect.
This dose has been used in the following experiments on u-PA-
dependent proliferation.
Effects of Raloxifene on synoviocyte proliferation
RAL inhibited cell proliferation in a dose-dependent manner in
both normal (p < 0.001) and RA synoviocytes (p < 0.001),
reaching a maximal effect at 1 µM (Fig. 2a). The RAL induced
decrease in cell proliferation did not significantly differ
between RA and healthy synoviocytes for any RAL dose.
These results indicate that RAL exerts an anti-proliferative
effect on both healthy and RA synoviocytes that is effective at
doses as small as 0.5 µM.
Effects of Raloxifene on u-PA-dependent proliferation
In both normal and RA synovial cells, RAL significantly
reduced u-PA- and 10% FCS-dependent proliferation (p <
0.001) (Fig. 2b). RA synoviocytes are as prone as normal syn-
oviocytes to spontaneous (0.2% FCS) proliferation and to pro-
liferation challenged both with 10% FCS and 500 ng/ml u-PA
(Fig. 2b). In particular, serum-dependent proliferation (10%
FCS) did not significantly differ from u-PA-dependent prolifer-
ation in both healthy and RA cell lines.
The proliferative effect elicited by 500 ng/ml of u-PA in 0.2%
FCS was significantly reduced by the mAb antagonists of u-
PA (mAb 5B4) and u-PAR (mAb 3936) in healthy (p < 0.001)
and RA synoviocytes (p < 0.001) (Fig. 2b). This indicates that
u-PA/u-PAR interaction is required for the pro-proliferative
effect of u-PA on normal and RA synoviocytes.
RAL blocked both FCS-dependent and u-PA-dependent pro-
liferation to a similar extent. RAL reduction of u-PA-dependent
proliferation was similar to the inhibition caused by the antag-
onist antibodies (p < 0.001 in normal and RA synoviocytes)
(Fig. 2b) and was not increased by co-treatment with them,
indicating a common target for RAL and anti u-PA/u-PAR anti-
bodies (data not shown). This suggests that inhibition of the
expression of critical members of the cell-associated fibrino-
lytic system is a likely target of RAL treatment.Available online http://arthritis-research.com/content/7/6/R1244
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u-PA, u-PAR and PAI-1 levels in normal and RA 
synoviocytes
As our ELISA assay for u-PA measures u-PA antigen inde-
pendent of its interaction with PAI-1, the data shown in Fig. 3a
indicate that u-PA released into the culture medium by RA syn-
oviocytes was significantly lower than u-PA produced by
healthy synoviocytes (3.1 ± 0.4 versus 10.05 ± 0.04 ng/106
cells, respectivle; p < 0.05).
A zymographic assay of u-PA performed on aliquots of the cul-
ture medium confirmed the data obtained using antibodies.
Culture mediums of RA synoviocytes display a lower u-PA
activity than medium obtained from healthy synoviocytes (Fig.
4a).
The direct fibrinolytic assay, performed on fibrin plates as
described, indicated the following: the culture medium of
healthy synoviocytes showed a higher fibrinolytic activity than
RA synoviocytes, thus confirming the data obtained with
zymography, again indicating lower constitutive u-PA produc-
tion in RA synoviocytes (Fig. 4b, left side); and the fibrinolytic
activity exhibited by aliquots of the acidic wash was slightly
higher in RA than in healthy synoviocytes (Fig. 4b, right side).
This means that, regardless of the lower amount of secreted u-
PA, a larger availability of u-PAR on the surface of RA synovi-
ocytes enabled RA synovial cells to bind a higher amount of
the ligand. These results have also been confirmed by radioli-
gand binding experiments. Healthy synoviocytes exhibited 95
± 15 × 103 u-PAR/cell, with a Kd ranging from 1.75 to 1.85
nM, and the receptor number was 140 ± 25 × 103/cell follow-
ing acidic treatment prior to performing binding experiments.
RA synoviocytes had 180 ± 30 × 103 uPAR/cell before and
230 ± 48 × 103 u-PAR/cell after acidic wash, while the Kd did
not change. Higher levels of u-PAR are found in cell lysates of
RA than of healthy synoviocytes (23.6 ± 0.10 versus 9.2 ±
Figure 1
Urokinase-type plasminogen activator u-PA/u-PA receptor-dependent  proliferation in healthy (H) and rheumatoid arthritis (RA) synoviocytes Urokinase-type plasminogen activator u-PA/u-PA receptor-dependent 
proliferation in healthy (H) and rheumatoid arthritis (RA) synoviocytes. 
Synoviocytes were seeded in 24 multi-well plates (15,000 cells/well) 
with 10% FCS in RPMI 1640. After 48 h incubation, cells were washed 
three times with serum-free medium and incubated in 0.2% FCS 
medium for an additional 48 h. At this time, cells were incubated for 48 
h in 0.2% FCS containing increasing concentrations of u-PA (50 to 
1,000 ng/ml). Proliferation of H and RA synoviocytes is reported as a 
function of u-PA concentration. Each point represents the mean ± 
standard deviation of three experiments performed in triplicate on four 
normal and four RA synovial cell lines.
Figure 2
Effects of Raloxifene (RAL) on proliferation in healthy (H) and rheuma- toid arthritis (RA) synoviocytes Effects of Raloxifene (RAL) on proliferation in healthy (H) and rheuma-
toid arthritis (RA) synoviocytes. (a) Proliferation of H and RA synovio-
cytes as a function of RAL concentration. Synoviocytes were seeded in 
24 multi-well plates (15,000 cells/well) with 10% FCS in RPMI 1640. 
After 24 h incubation, cells were treated with increasing concentrations 
of RAL (0.5 to 2 µM). (b) Proliferation of H and RA synoviocytes under 
control conditions (0.2% FCS as a negative control, and 10% FCS as a 
positive control), in 0.2% FCS under the effect of 500 ng/ml urokinase-
type plasminogen activator (u-PA) and in the presence of 0.5 and 1 µM 
RAL or the monoclonal antibodies (mAbs) 5B4 and 3936, which impair 
u-PA/u-PAR binding (see text for details). In both (a) and (b), each 
point represents the mean ± standard deviation of three experiments 
performed in triplicate on four normal and four RA synovial cell lines. § 
= p < 0.01 versus basal (0.2% FCS); # = p < 0.001 versus 10% FCS 
or u-PA, for both H and RA.Arthritis Research & Therapy    Vol 7 No 6    Guiducci et al.
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0.05 ng/106 cells, respectively; p < 0.05), also determined
using ELISA (Fig. 3b).
Moreover, RA synovial cells release into culture medium higher
amounts of PAI-1 than healthy synoviocytes (5.5 ± 0.1 versus
2.9 ± 0.1 µg/106 cells, respectively; p < 0.05; Fig. 3c).
Effects of Raloxifene on u-PA, u-PAR and PAI-1 levels in 
normal and rheumatoid arthritis synoviocytes
RAL reduces u-PA levels in healthy and RA synoviocytes (p <
0.0001; Fig. 3a). It does this dose dependently: 1 µM RAL is
more efficient than 0.5 µM in healthy (p < 0.01) and in RA syn-
oviocytes (p < 0.05). RAL-dependent reduction of u-PA levels
Figure 3
Fibrinolytic pattern of healthy (H) and rheumatoid arthritis (RA) synoviocytes treated with Raloxifene Fibrinolytic pattern of healthy (H) and rheumatoid arthritis (RA) synoviocytes treated with Raloxifene. Samples were analyzed both in basal conditions 
and after treatment with 0.5 and 1 µM Raloxifene (48 h). (a) Urokinase-type plasminogen activator (u-PA) antigen was quantified on aliquots of the 
culture medium by ELISA assay and reported as ng/106 synovial cells. (b) u-PA receptor (u-PAR) was quantified by ELISA assay on aliquots of cell 
lysates and reported as ng/106 synovial cells. (c) Plasminogen activator inhibitor (PAI)-1 was also measured in aliquots of the culture medium, and 
reported as µg/106 synovial cells. H refers to four different synovial cell cultures from healthy individuals, RA refers to synovial cell cultures from four 
different rheumatoid arthritis patients. In (a-c), each point represents the mean ± standard deviation of three experiments performed in triplicate on 
each synovial cell line. § = p < 0.01 versus basal (0.2% FCS).Available online http://arthritis-research.com/content/7/6/R1244
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at 0.5 µM and 1 µM is significantly higher (p < 0.05) in healthy
than in RA synoviocytes.
A zymographic assay performed on culture medium treated
with 0.5 µM and 1 µM RAL confirmed the data obtained with
the u-PA assay. In fact, RAL reduces the u-PA enzymatic
activity in a dose dependent manner, in both healthy and RA
synoviocytes (Fig. 4a).
The direct fibrinolytic assay on fibrin plates, performed with
aliquots of culture medium, indicated that RAL-dependent
reduction of cell-associated fibrinolytic activity is more pro-
nounced in RA than in normal synoviocytes (Fig. 4b, left side).
Fig. 4b (right side) shows a RAL-dependent reduction of u-PA
in the acidic wash of both normal and RA synoviocytes.
RAL significantly reduces u-PAR levels in cell lysates from RA
synoviocytes (p < 0.0001; Fig. 3b); 1 µM RAL is more efficient
than 0.5 µM at reducing u-PAR levels in healthy and RA syn-
oviocytes (p < 0.01). The effect of 0.5 µM and 1 µM RAL is
significantly higher in RA than in healthy synoviocytes (p <
0.05). Radioligand binding experiments showed that, upon
RAL treatment, the receptor number before and after acidic
treatment was similar in healthy synoviocytes, whereas a dra-
matic decrease of both unoccupied u-PAR (85 ± 18 × 103
receptor/cell, before acidic wash) and total u-PAR (150 ± 25
× 103 receptor/cell after acidic wash) was observed in RA
synoviocytes.
RAL significantly increases PAI-1 levels in healthy and RA syn-
oviocytes (p < 0.0001; Fig. 3c). This is true for both 0.5 µM
and 1 µM RAL (healthy synoviocytes, p < 0.01 and p < 0.001,
respectively; RA synoviocytes, p < 0.001 and p < 0.01,
respectively). RAL 1 µM is more efficient than RAL 0.5 µM at
increasing PAI-1 levels in both healthy and RA synoviocytes (p
< 0.001). RAL 0.5 µM and 1 µM have a significantly higher
effect on increasing PAI-1 levels in RA than in healthy synovi-
ocytes (p < 0.05).
u-PA-dependent synoviocyte chemoinvasion
u-PA-dependent chemoinvasion was dose-dependent (Fig.
5a), with a maximal effect at 100 ng/ml for both healthy and RA
synoviocytes. Basal migration was more pronounced (more
than 40%) in RA than in healthy synoviocytes. This difference
is maintained at each concentration of u-PA in the lower well
of the migration chamber. An increase in invasion observed
after a 5 h incubation with 100 ng/ml u-PA was counteracted
by the incubation of invasive cells with mAb antagonists of u-
PA (mAb 5B4) and u-PAR (mAb 3936) (Fig. 5b). This indi-
cates that u-PA/u-PAR interaction is required for the pro-inva-
sive effect of u-PA on normal and RA synoviocytes.
Effects of Raloxifene on u-PA-dependent synoviocyte 
chemoinvasion
RAL inhibits cell chemoinvasion in a dose-dependent manner
in both normal and RA synoviocytes, reaching a maximum at 1
µM (Fig. 5B); this decrease did not significantly differ between
healthy and RA cells at any RAL dose.
RAL significantly reduced u-PA-induced chemoinvasion in
healthy and RA synoviocytes; 1 µM RAL reduced chemoinva-
sion to basal values. When cells were incubated together with
RAL in the upper chamber, it caused similar effects on chem-
oinvasion. In fact, RAL was able to inhibit migration induced by
Figure 4
Urokinase-type plasminogen activator (u-PA) activity in healthy (H) and  rheumatoid arthritis (RA) synoviocytes treated with Raloxifene (RAL) Urokinase-type plasminogen activator (u-PA) activity in healthy (H) and 
rheumatoid arthritis (RA) synoviocytes treated with Raloxifene (RAL). 
Samples were analyzed both in basal conditions and after treatment 
with 0.5 and 1 µM RAL (48 h). (a) Zymographic assay of aliquots of the 
culture medium. u-PA digestion of plasminogen shows clear bands of 
lysis in the cloudy casein background of the indicating layer. Shown 
here are the effects on one H and one RA line; the other lines furnished 
similar results. (b) Direct fibrinolytic assay of cell membrane-associated 
plasminogen activators. Left side: lysis areas of culture medium under 
the indicated experimental conditions. Right side: lysis areas of aliquots 
of the acidic wash (Ac), indicating the activity eluted from the cell sur-
face. The diameter (mm) of the lysis areas were measured as an index 
of fibrin digestion. H refers to four different synovial cell cultures from 
healthy individuals; RA refers to synovial cell cultures from four different 
RA patients Each point represents the mean ± standard deviation of 
three experiments performed in triplicate on each synovial cell line. § = 
p < 0.01 versus control (C).Arthritis Research & Therapy    Vol 7 No 6    Guiducci et al.
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u-PA in a dose-dependent way with a maximal action at a dose
of 1 µM and this decrease in mobility was proportionally similar
in healthy and RA synoviocytes (data not shown).
Upon combining the results shown in Figs 3, 4 and 5, one is
tempted to think that RAL works mainly through the reduction
in the levels of u-PAR and, therefore, by blocking u-PA-
dependent chemoinvasion. In fact, the RAL reduction of u-PA-
dependent migration was similar to the inhibition caused by
the antagonist mAbs (Fig. 5b) and is not increased by co-treat-
ment with them, indicating that RAL and anti-u-PA/u-PAR anti-
bodies have a common target (data not shown).
Discussion
This is the first study on the effects of RAL on RA synoviocytes
and on their fibrinolytic pattern and function. The presence of
functional estrogen receptors (ER-alpha) in synoviocytes has
been identified [7,29]. Our data show that RAL acts as an
inhibitor of the fibrinolytic system, exhibiting similar effects on
both healthy and RA synoviocytes, with the activity on RA syn-
oviocytes being more pronounced. Indeed, the drug inhibits
cell proliferation and chemoinvasion in a dose-dependent
manner, reduces u-PA and u-PAR levels, increases PAI-1 lev-
els and blocks u-PA by acting on the specific interaction
between u-PA and u-PAR.
Despite increasing evidence on the significance of sex hor-
mones in RA, their etiopathological role and potential long
term effect on RA progression still remain unclear. Also, the
link between sex hormones and the fibrinolytic system is still to
be elucidated in RA synovial cells.
In human breast cancer cells, estradiol inhibited the expres-
sion and secretion of u-PA, t-PA and PAI-1 proteins. Zymogra-
phy confirmed the inhibitory effect of estradiol on u-PA activity
[30]. The regulation of expression of genes encoding u-PA
and PAI-1 by estradiol and different SERMs has been
described in human breast cancer cells [31]. Two different
SERMS (4-hydroxytamoxifen and RAL) had a concentration-
dependent agonistic (estradiol-like) effect on the regulation of
these genes. In contrast, a pure anti-estrogen alone had no
effect but could block the action of estradiol and SERMs. This
demonstrates that RAL has an estrogen-like effect on human
breast cancer cells with respect to the regulation of u-PA and
PAI-1 gene expression [31].
These findings prompted us to investigate the effects of RAL
on the fibrinolytic system of RA synovial cells. In fibroblast-like
synoviocytes, we found a link between the functionality of
another proteolityc system (the u-PA/u-PAR-PAI-1 system)
and a SERM such as RAL. In RA, the formation and invasive-
ness of synovial pannus, supported by angiogenesis, is linked
to serine proteinases, mainly u-PA [11], produced in high
quantity by synoviocytes [12,18,19].
The u-PA/u-PAR-PAI-1 system is an organizer of cell-ECM
contacts and covers the full range of activities required to pro-
mote invasion and angiogenesis and to disrupt cell attachment
sites. We have recently shown that RA synoviocytes display a
fibrinolytic machinery (u-PA, u-PAR and PAI-1) addressed
toward an invasive pattern [19]. RAL inhibits the proliferation
of RA synoviocytes dose dependently and blocks the prolifer-
ation induced by u-PA, mainly by reducing u-PAR levels with-
out affecting the Kd of the u-PA/u-PAR interaction (as shown
Figure 5
Urokinase-type plasminogen activator (u-PA)/u-PA receptor (u-PAR)- dependent chemoinvasion in healthy (H) and rheumatoid arthritis (RA)  synoviocytes Urokinase-type plasminogen activator (u-PA)/u-PA receptor (u-PAR)-
dependent chemoinvasion in healthy (H) and rheumatoid arthritis (RA) 
synoviocytes. (a) Cell invasion of Matrigel-coated filters by H and RA 
synoviocytes as a function of u-PA concentration. Migration was stimu-
lated by increasing concentrations of u-PA (5 to 250 ng/ml) in the lower 
well of the migration chamber. (b) Percent increase of Matrigel invasion 
in H and RA synoviocytes treated with Raloxifene (RAL) or neutralizing 
antibodies. Basal, invasion of H and RA synovial cells in the presence of 
0.2% FCS in the lower well; C+, invasion stimulated by conditioned 
medium of A431 cell line, used as a sure chemotactic agent; RAL 0.5 
and RAL 1, invasion challenged with 0.5 µM and 1 µM RAL in the lower 
well; u-PA, invasion challenged with 100 ng/ml of u-PA in the lower 
well; u-PA+RAL 0.5 and u-PA+RAL 1, invasion challenged with 100 
ng/ml u-PA in the presence of 0.5 and 1 µM RAL in the lower well; u-
PA+5B4 and u-PA+3936, invasion challenged with 100 ng/ml u-PA in 
the presence of 1.5 µg/ml of monoclonal antibodies 5B4 and 3936 in 
the lower and upper well, respectively. In (a) and (b), each point repre-
sents the mean ± standard deviation of three experiments performed in 
triplicate on four normal and four RA synovial cell lines. § = p < 0.01 
versus basal (0.2% FCS); # = p < 0.001 versus u-PA, for both H and 
RA.Available online http://arthritis-research.com/content/7/6/R1244
R1252
in this study by ELISA and radioligand binding experiments)
and, therefore, by reducing the specific interaction between u-
PA and u-PAR following reduction of u-PAR.
Cellular migration, linked to cellular adhesiveness, is an impor-
tant process for the invasion of articular cavity and extra-artic-
ular tissues, typical of RA. Our data show that RAL inhibits
migration of RA synoviocytes, thus potentially contributing to
the modulation of the growth of synovial pannus. u-PAR regu-
lates pericellular proteolysis and cell surface adhesion recep-
tors, fundamental events in the first steps of invasion and
angiogenesis. RAL further reduces u-PA levels derived from
RA synoviocytes, thus potentially reducing the invasive and
angiogenetic potential of these cells.
The increased expression of PAI-1 in RA synoviocytes is in
agreement with previous data showing higher production of
PAI-1 in cultured RA synoviocytes [12,19]. In RA, elevated
PAI-1 levels could act as an ECM-stabilizing molecule by
blocking extracellular proteolysis, thus providing cells with a
substrate favoring cell movement. At the same time, PAI-1 pro-
motes cell detachment [32]. RAL increases PAI-1, thereby
blocking the u-PA-dependent ECM degradation and reducing
cell movement. The whole in vitro scenario is that RAL reduces
u-PAR and u-PA levels and increases PAI-1 levels. This action
may significantly contribute to reducing the pro-invasive and
pro-angiogenic pattern of RA synoviocytes, although the clini-
cal relevance of these findings require further study.
The over-expression of u-PAR in RA may depend on the need
to activate the fibrinolytic pathway in order to degrade and
invade ECM, as well as to promote interaction between u-PAR
and vitronectin, which provides the adhesive grip necessary
for cell locomotion, events required in all the invasive patholo-
gies [33]. RAL seems to exert an upstream blocking of the
membrane-bound fibrinolytic system, which also stops the
proteolytic activities of MMPs.
Conclusion
RAL modulates in vitro the components and functionality of
the membrane-bound fibrinolytic system, exhibiting a more
intense activity in RA synoviocytes compared to their normal
counterpart. RAL inhibits u-PA-induced proliferation and u-PA-
induced cell migration dose dependently. The effect of RAL in
the reduction of the formation of synovial pannus and the radi-
ological progression of RA warrants further study.
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